PIŚMIENNICTWO

1. Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde 1817; 3: 1-25.

2. Kerner J. Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geräucherter Würste. Tübingen: Osiander 1820.

3. Kerner J. Das fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Tübingen: Cotta 1822.

4. Van Ermengen EP. Über einen neuen anaeroben Bacillus und seine Beziehnung zum Botulismus. Z Hyg Infektionskrankh1897; 26: 1-56.

5. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734-770.

6. Foreword SAB. [In:] with Botulinum Toxin. Jankovic J, Hallett M (eds.). Therpay New York: Marcel Dekker, Inc. 1994, pp. vii-ix.

7. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-596.

8. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 2003; 162: 1293-1303.

9. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999; 354: 259-268.

10. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-835.

11. Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994; 269: 1617-1620.

12. Hunt T, Clarke K, Rupp D, et al. Secondary cleavage of a fluorescently labeled SNAP – 25 substrate by Xeomins drug product. Toxicon 2008; 51: 13.

13. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci 1971; 14: 47-60.

14. Dressler D. Botulinum Toxin Therapy. Stuttgart, New York: Thieme Verlag.

15. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999; 96 (6): 3200-3205.

16. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000; 44: 106-109.

17. Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002; 365: R17.

18. Morris J, Jobling P, Gibbins I. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281 :2124-2132.

19. Shone CC, Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992; 207: 1009-1016.

20. Mahowald ML, Singh JA, Dykstra D. Long term effects of intraarticular botulinum toxin A for refractory joint pain. Neurotox Res 2006; 9:179-188.

21. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552-555.

22. Arezzo JC, Litwak MS, Caputo FA, Meyer KE, Shopp GM. Spread of paralysis to nearby and distant noninjected muscles in a monkey hand model: comparison of bont-b and bont-a. [In:] Scientific and Therapeutic Aspects of Botulinum Toxin. Brin M, Jankovic J, Hallett M (eds.). Lipincott&Williams, Philadelphia 2002, pp123-133

23. Alcalay RN, Simoes RM, Feigin A. Neuralgic amyotrophy following botulinum toxin injection. Parkinsonism Relat Disord 2010; 16: 301-302.

24. Onoue H, Matsunobu A, Nagaishi A, Yukitake M, Kuroda Y. A case report of acute polyradiculoneuritis developing after multiple injections of botulinum toxin for cervical dystonia. Rinsho Shinkeigaku 2004; 44: 20-24.

25. Dressler D, Adib Saberi F. First high dose use of complex free botulinum toxin type A. Mov Disord 2006; 21 (Suppl 15): S640.

26. Wissel J, Ward AB, Erztgaart P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009; 41: 13-25.

27. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006; 296 (20): 2476-2479.

28. Wiegand H, Erdmann G, Wellhöner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292 (2): 161-165.

29. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008; 28 (14): 3689-3696.

30. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992; 12 (2): 121-127.

31. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59 (3): 418-420.

32. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R. A long-term follow-up of botulinum toxin A in cervical dystonia. Kollewe Neurol Res 2009; 31 (5): 463-466.

33. Sławek J, Car H, Bonikowski M, et al. Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications. Neurol Neurochir Pol 2010; 44 (1): 43-64.

34. Claypool DW, Duane DD, Ilstrup DM, et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minesota. Mov Disord 1995; 10: 608-614.

35. Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci 1996; 23: 194-197.

36. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 1998; 64: 13-17.

37. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16: 316-323.

38. Truong D, Comella C, Fernandez HH, Ondo WG. Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14: 407-414.

39. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011; 308: 103-109.

40. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.

41. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.

42. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-707.

43. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Neurology 2008; 70: 1699.

44. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18: 5-18.

45. Jankovic J, David Charles P, Adler CH, et al. Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) Baseline Demographic and Clinical Characteristics. Poster presented at American Academy of Neurology (AAN), March 16-23, 2013, San Diego, CA, USA.

46. Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000; 15 (1): 150-153.

47. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 2007; 22 (2): 95-100.

48. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 2006; 13 Suppl 1: 21-29.

49. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. J. Neurol. Neurosurg. Psychiatry 1988; 3: 188-194.

50. Hallett M, Evinger C, Jankovic J, Stacy M. BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008; 71 (16): 1275-1282.

51. Weiss EM, Hershey T, Karimi M, et al. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 2006; 21 (8): 1175-1181.

52. Jordan DR, Anderson DL, Digre KB. Apraxia of lid opening in blepharospasm. Ophthalmic Surg 1990; 21: 331-334.

53. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord 2011; 26: 1521-1528.

54. Roggenkamper P, Jost WH, Bihari K., Comes G., Grafe S. Efficacy and safety of a new botulinum toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-312.

55. Wabbels B, Reichel G, Fulford-Smith A, Wright N. Roggenkamper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J. Neural Transm 2011; 118: 233-239.

56. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord 1996; 11: 27-31.

57. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616-623.

58. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197-199.

59. Truong D, Comella C, Fernandez HH, Ondo WG. Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14: 407-414.

60. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A–dysport and botox–assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018.

61. Jost WH, Kohl A. Botulinum toxin: evidence based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248 (suppl. 1): 21-24.

62. Albanese A, Bentivoglio AR, Colosimo C, et al. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients, J Neurol Neurosurg Psychiatry 1996; 60: 693-694.

63. Levy RL, Berman D, Parikh M, Miller NR. Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 2006; 113 (9): 1665-1668.

64. Ochudlo S, Bryniarski P, Opala G. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord 2007; 13 (8): 505-508.

65. Calace P, Cortese G, Piscopo R, et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 2003; 13 (4): 331-336.

66. Meige H. Les convulsions de la face. Ue forme clinique de convulsion faciale bilaterale et mediane. Rev Neurol (Paris) 1910; 21: 437-443.

67. Schneider SA, Aggarwal A, Bhatt M, et al. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 2006; 67 (6): 940-943.

68. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616-623.

69. Lee SJ, McCall Jr. WD, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 2010; 89: 16-23.

70. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatr 2007; 78: 264-270.

71. Contarino MF, Kruisdijk JJ, Koster L, et al. Sensory integration in writer’s cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol 2007; 118: 2195-2206.

72. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord 1995; 10: 466-471.

73. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 1993; 43: 183-185.

74. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992; 42: 627-630.

75. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998; 21 (12): 1740-1747.

76. Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol 1990; 47: 1233-1234.

77. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992; 15: 1045-1049.

78. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248 (supl. 1): 21-24.

79. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-639.

80. Lance JW. Disordered muscle tone and movement. Clin Exp Neurol 1981; 18: 27-35.

81. Koman LA, Mooney JF III, Smith B, et al. Management of cerebral palsy with botulinum – A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489-495.

82. Simpson DM, Gracies J-M, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology 2008; 70: 1691.

83. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347:395-400.

84. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265-269.

85. Kanovský P, Sławek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009; 32 (5): 259-265.

86. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-515.

87. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Neurology 2008; 70: 1707.

88. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-Week PREEMPT clinical program. Headache 2011; 51: 1358-1373.